Métadonnées
Afficher la notice complètePartager cette publication !
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
Langue
EN
Article de revue
Ce document a été publié dans
Antimicrobial Agents and Chemotherapy. 2019-01-01, vol. 63, n° 1
Résumé en anglais
A clinical isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from ...Lire la suite >
A clinical isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed an increased hydrolytic activity toward carbapenems and to ceftolozane and a decreased susceptibility to β-lactamase inhibitors compared to GES-1, except for avibactam. We show here that resistance to ceftolozane-tazobactam may occur through acquisition of a specific ESBL in but that ceftazidime-avibactam combination remains an effective alternative.< Réduire
Mots clés en anglais
Amino Acid Substitution
Anti-Bacterial Agents
Azabicyclo Compounds
Carbapenems
Ceftazidime
Cephalosporins
Drug Combinations
Gene Expression
Humans
Microbial Sensitivity Tests
Pseudomonas Infections
Pseudomonas aeruginosa
Tazobactam
beta-Lactam Resistance
beta-Lactamases
Unités de recherche